PL3116908T3 - Humanizowane przeciwciała kir3dl2 - Google Patents

Humanizowane przeciwciała kir3dl2

Info

Publication number
PL3116908T3
PL3116908T3 PL15709212T PL15709212T PL3116908T3 PL 3116908 T3 PL3116908 T3 PL 3116908T3 PL 15709212 T PL15709212 T PL 15709212T PL 15709212 T PL15709212 T PL 15709212T PL 3116908 T3 PL3116908 T3 PL 3116908T3
Authority
PL
Poland
Prior art keywords
humanized
kir3dl2 antibodies
kir3dl2
antibodies
humanized kir3dl2
Prior art date
Application number
PL15709212T
Other languages
English (en)
Inventor
Laurent Gauthier
Nicolas Schneider
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of PL3116908T3 publication Critical patent/PL3116908T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL15709212T 2014-03-14 2015-03-12 Humanizowane przeciwciała kir3dl2 PL3116908T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953035P 2014-03-14 2014-03-14
PCT/EP2015/055224 WO2015136052A1 (en) 2014-03-14 2015-03-12 Humanized antibodies with increased stability
EP15709212.3A EP3116908B1 (en) 2014-03-14 2015-03-12 Humanized kir3dl2 antibodies

Publications (1)

Publication Number Publication Date
PL3116908T3 true PL3116908T3 (pl) 2020-01-31

Family

ID=52649047

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15709212T PL3116908T3 (pl) 2014-03-14 2015-03-12 Humanizowane przeciwciała kir3dl2

Country Status (18)

Country Link
US (4) US10280222B2 (pl)
EP (2) EP3116908B1 (pl)
JP (1) JP6722110B2 (pl)
KR (1) KR102345173B1 (pl)
CN (1) CN106132989B (pl)
AU (1) AU2015228815B2 (pl)
BR (1) BR112016021066B1 (pl)
CA (1) CA2939204C (pl)
DK (1) DK3116908T3 (pl)
ES (1) ES2747799T3 (pl)
HU (1) HUE046308T2 (pl)
IL (1) IL247371B (pl)
MX (1) MX380265B (pl)
PL (1) PL3116908T3 (pl)
PT (1) PT3116908T (pl)
RU (1) RU2684703C2 (pl)
SG (1) SG11201606789SA (pl)
WO (1) WO2015136052A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771029A4 (en) * 2011-10-25 2015-07-01 Onclave Therapeutics Ltd ANTIBODY FORMULATIONS AND METHOD THEREFOR
JP6507097B2 (ja) 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
ES2747799T3 (es) 2014-03-14 2020-03-11 Innate Pharma Anticuerpos para KIR3DL2 humanizados
KR102669294B1 (ko) 2015-02-19 2024-05-23 컴퓨젠 엘티디. 항-pvrig 항체 및 사용 방법
SI3347379T1 (sl) 2016-08-17 2020-04-30 Compugen Ltd. ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
AU2017345203B2 (en) 2016-10-21 2024-08-01 Innate Pharma Treatment with anti-KIR3DL2 agents
WO2019011855A1 (en) * 2017-07-10 2019-01-17 Innate Pharma ANTIBODIES NEUTRALIZING SIGLEC-9
CN108279302B (zh) * 2017-07-11 2020-05-26 深圳市伯劳特生物制品有限公司 一种用于酶联免疫试剂盒的组合物以及幽门螺旋杆菌抗体谱检测试剂盒及其制备方法
CA3125945A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
TWI764248B (zh) * 2019-08-23 2022-05-11 大陸商四川海思科製藥有限公司 肽醯胺類組合物及其製備
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度
AU2023245103A1 (en) * 2022-03-28 2024-10-24 Fortvita Biologics (Singapore) Pte. Ltd. Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof.
WO2025245386A1 (en) * 2024-05-23 2025-11-27 La Jolla Institute For Immunology Kir3dl2 as an anti-cancer target
WO2025261953A1 (en) 2024-06-18 2025-12-26 Innate Pharma Stable aqueous formulations comprising lacutamab

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE556092T1 (de) 2000-12-18 2012-05-15 Inst Nat Sante Rech Med Mittel zur diagnose und therapie von ctcl
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US20050058661A1 (en) 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CA2608818A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
SI2573114T1 (sl) 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
EP2322557B1 (en) * 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
AU2007226752A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2010081890A1 (en) 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
WO2012160448A2 (en) * 2011-05-25 2012-11-29 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
JP6507097B2 (ja) * 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
US10246510B2 (en) 2012-09-19 2019-04-02 Innate Pharma KIR3DL2 binding agents
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
ES2747799T3 (es) 2014-03-14 2020-03-11 Innate Pharma Anticuerpos para KIR3DL2 humanizados
AU2017345203B2 (en) 2016-10-21 2024-08-01 Innate Pharma Treatment with anti-KIR3DL2 agents
CA3125945A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma

Also Published As

Publication number Publication date
ES2747799T3 (es) 2020-03-11
RU2016133463A3 (pl) 2018-08-16
MX380265B (es) 2025-03-12
US12227569B2 (en) 2025-02-18
US10280222B2 (en) 2019-05-07
US20250230237A1 (en) 2025-07-17
US20190276536A1 (en) 2019-09-12
RU2016133463A (ru) 2018-04-16
US20170158763A1 (en) 2017-06-08
EP3116908A1 (en) 2017-01-18
RU2684703C2 (ru) 2019-04-11
JP2017510569A (ja) 2017-04-13
EP3116908B1 (en) 2019-06-26
BR112016021066B1 (pt) 2024-01-02
CN106132989B (zh) 2020-06-19
JP6722110B2 (ja) 2020-07-15
CA2939204A1 (en) 2015-09-17
US11066470B2 (en) 2021-07-20
AU2015228815A1 (en) 2016-09-01
AU2015228815B2 (en) 2020-08-27
BR112016021066A2 (pt) 2018-01-23
SG11201606789SA (en) 2016-09-29
MX2016011748A (es) 2016-12-12
WO2015136052A1 (en) 2015-09-17
DK3116908T3 (da) 2019-10-07
IL247371A0 (en) 2016-11-30
EP3572431A1 (en) 2019-11-27
PT3116908T (pt) 2019-10-09
HUE046308T2 (hu) 2020-02-28
IL247371B (en) 2021-06-30
CA2939204C (en) 2023-06-27
US20210340254A1 (en) 2021-11-04
KR20170002368A (ko) 2017-01-06
CN106132989A (zh) 2016-11-16
KR102345173B1 (ko) 2021-12-29

Similar Documents

Publication Publication Date Title
IL288649A (en) Human antibodies against tau
ZA201803874B (en) Humanized anti-cd73 antibodies
IL250415A0 (en) Antibodies against pd-l1
IL250583A0 (en) Anti-tigit antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL247277A0 (en) Monoclonal antibodies against Ebola
PT3101131T (pt) Anticorpo antitranstirretina humanizado
IL256579A (en) Human antibodies
PL3116908T3 (pl) Humanizowane przeciwciała kir3dl2
IL248402A0 (en) Humanized antibodies against ceacam1
EP3131581A4 (en) Humanized anti-tf-antigen antibodies
IL250374B (en) Antibodies against ceramide
IL250404A0 (en) A new anti-igbeta antibody of human origin
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies